Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.2%

Eli Lilly and Company (NYSE:LLY)’s share price was up 1.2% during mid-day trading on Tuesday . The company traded as high as $741.20 and last traded at $739.90. Approximately 412,280 shares changed hands during trading, a decline of 86% from the average daily volume of 3,028,952 shares. The stock had previously closed at $731.33.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on LLY shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a research report on Monday, April 15th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. The Goldman Sachs Group raised their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Finally, Truist Financial restated a “buy” rating and issued a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Up 1.8 %

The firm’s 50 day moving average is $763.83 and its two-hundred day moving average is $662.78. The firm has a market cap of $707.33 billion, a P/E ratio of 127.57, a price-to-earnings-growth ratio of 1.58 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period last year, the company posted $2.09 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by corporate insiders.

Institutional Trading of Eli Lilly and Company

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Masso Torrence Wealth Management Inc. acquired a new position in Eli Lilly and Company during the first quarter worth $476,000. Birinyi Associates Inc. increased its holdings in Eli Lilly and Company by 64.2% during the first quarter. Birinyi Associates Inc. now owns 2,675 shares of the company’s stock worth $2,081,000 after buying an additional 1,046 shares during the last quarter. Nations Financial Group Inc. IA ADV increased its holdings in Eli Lilly and Company by 206.4% during the first quarter. Nations Financial Group Inc. IA ADV now owns 6,122 shares of the company’s stock worth $4,763,000 after buying an additional 4,124 shares during the last quarter. TrueWealth Advisors LLC increased its holdings in Eli Lilly and Company by 11.5% during the first quarter. TrueWealth Advisors LLC now owns 1,185 shares of the company’s stock worth $922,000 after buying an additional 122 shares during the last quarter. Finally, Tyche Wealth Partners LLC increased its holdings in Eli Lilly and Company by 29.9% during the first quarter. Tyche Wealth Partners LLC now owns 4,009 shares of the company’s stock worth $3,118,000 after buying an additional 923 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.